Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse LimbEvents.

Abstract

Lp(a) (lipoprotein[a])-lowering therapy to reduce cardiovascular disease is under investigation in phase 3 clinical trials. High Lp(a) may be implicated in peripheral artery disease (PAD), abdominal aortic aneurysms (AAAs), and major adverse limb events (MALE). The authors investigated the association of high Lp(a) levels and corresponding LPA genotypes with risk of PAD, AAA, and MALE. The authors included 108,146 individuals from the Copenhagen General Population Study. During follow-up, 2,450 developed PAD, and 1,251 AAAs. Risk of MALE was assessed in individuals with PAD at baseline and replicated in the Copenhagen City Heart Study. Higher Lp(a) was associated with a stepwise increase in risk of PAD and AAA (P for trend<0.001). For individuals with Lp(a) levels≥99th (≥143mg/dL, ≥307nmol/L) vs<50th percentile (≤9mg/dL,≤17nmol/L), multivariable-adjusted HRs were 2.99 (95%CI: 2.09-4.30) for PAD and 2.22 (95%CI: 1.21-4.07) for AAA. For individuals with PAD, the corresponding incidence rate ratio for MALE was 3.04 (95%CI: 1.55-5.98). Per 50mg/dL (105nmol/L) genetically higher Lp(a) risk ratios were 1.39 (95%CI: 1.24-1.56) for PAD and 1.21 (95%CI: 1.01-1.44) for AAA, consistent with observational risk ratios of 1.33 (95%CI: 1.24-1.43) and 1.27 (95%CI: 1.15-1.41), respectively. In women smokers aged 70 to 79 years with Lp(a)<50th and≥99th percentile, absolute 10-year risks of PAD were 8% and 21%, and equivalent risks in men 11% and 29%, respectively. For AAA, corresponding risks were 2% and 4% in women, and 5% and 12% in men. High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies.